SOHO 2024

Saad Z. Usmani, MD, MBA, FACPThe HemOnc Pulse | November 20, 2024
Dr. Usmani, of the Memorial Sloan Kettering Cancer Center, highlights multiple myeloma news from the SOHO 2024 conference.
Melissa BadamoMyeloma | November 14, 2024
A study demonstrated favorable outcomes among high-risk patients with newly diagnosed MM who received HSCT consolidation.
Melissa BadamoMyeloma | November 14, 2024
Cilta-cel plus lenalidomide maintenance provides deep and durable responses with no new safety signals in patients with MM.
Advertisement
Melissa BadamoMyeloma | November 14, 2024
Daratumumab-based induction therapy showed improved responses and comparable safety in newly diagnosed multiple myeloma.
Melissa BadamoMyeloma | November 14, 2024
Adding isatuximab to standard-of-care improved CR and MRD negativity rates in transplant-eligible, newly diagnosed MM.
Andrew MorenoChronic Myeloid Leukemia | November 13, 2024
Adverse events were common in patients with CML receiving first- or second-generation tyrosine kinase inhibitors.
Advertisement
Andrew MorenoChronic Lymphocytic Leukemia | November 13, 2024
Venetoclax plus ibrutinib was associated with lower rates of mortality and serious adverse events than the control regimens.
Andrew MorenoAcute Myeloid Leukemia | November 13, 2024
MDS-related gene mutations and number of mutations did not correlate with worse outcomes.
Andrew MorenoAcute Lymphoblastic Leukemia | November 13, 2024
The one-year overall survival rate of 90%, and the MRD negativity rate was 94%.
Melissa BadamoMyelofibrosis | November 4, 2024
Pacritinib demonstrated superiority to best available therapy for spleen volume reduction, total symptom score, and more.
Melissa BadamoMyelofibrosis | November 13, 2024
Patients with splenomegaly are more likely to be referred for HSCT.
Melissa BadamoMyelofibrosis | November 4, 2024
Selinexor plus ruxolitinib was well tolerated, reduced symptom burden, and led to spleen volume reduction.
Melissa BadamoMyelofibrosis | November 4, 2024
One year of pacritinib treatment stabilized or improved thrombocytopenia and anemia in patients with myelofibrosis.
Sangeetha Venugopal, MDThe HemOnc Pulse | November 1, 2024
Dr. Venugopal, of the Sylvester Comprehensive Cancer Center, shares MDS updates from the SOHO 2024 meeting.
Patrick DalyMyeloma | October 31, 2024
This real-world study characterized step-up dosing models for talquetamab in patients with multiple myeloma.
Patrick DalyMyeloma | October 31, 2024
Talquetamab and pomalidomide induced rapid and deep responses in patients with relapsed or refractory multiple myeloma.
Patrick DalyMyeloma | October 31, 2024
The iMMagine-3 randomized trial has begun enrollment of patients with relapsed or refractory multiple myeloma.
Patrick DalyMyeloma | October 31, 2024
OS, infections, hospitalization, and availability off the shelf were preferred treatment attributes of T-cell engagers.
Julie GouldMyelodysplastic Syndromes | October 28, 2024
A novel multivariate model improved risk stratification in MDS compared with both the IPSS-R and IPSS-M.
Julie GouldMyelodysplastic Syndromes | October 28, 2024
The rate of abnormal cytogenetics among AA patients with MDS is comparable to or lower than the general population.
Advertisement
Advertisement
Editorial Board